Sidebar: Antithrombotics: In A Crowded Field Of Candidates, Does Being First Matter?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The cresting wave of novel antithrombotic NDAs could mean 2010 will be a difficult year for FDA's Division of Cardiovascular and Renal Products, as the products have massive applications and tricky risk-benefit evaluations.
You may also be interested in...
Effient Review Delayed More By Management Issues Than Clinical Disputes
In FDA’s review of Lilly/Daiichi Sankyo’s antiplatelet agent Effient (prasugrel) – a drug with broad potential use – it is notable that the approval was delayed not by unusual clinical questions, but rather by the agency’s efforts to be exceedingly thorough and scrupulous in the review.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product